Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
18 Sep 2024
// BUSINESSWIRE
04 Sep 2024
// BUSINESSWIRE
26 Aug 2024
// BUSINESSWIRE
22 Aug 2024
// BUSINESSWIRE
20 Aug 2024
// BUSINESSWIRE
08 Aug 2024
// BUSINESSWIRE
Details:
IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Lead Product(s): IGC-AD1
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2024
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
Details : IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2024
Details:
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2024
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IGC Pharma Advances IGC-AD1 Toward Alzheimer’s Plaque Clinical Trials
Details : IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Details:
IGC-1A is a potential new GLP-1 agonist. Currently, it is being evaluated in the discovery stage for the treatment of patients suffering from diabetes.
Lead Product(s): IGC-1A
Therapeutic Area: Endocrinology Brand Name: IGC-1A
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2024
Lead Product(s) : IGC-1A
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IGC Pharma Expands Portfolio with GLP-1 Agonist for Metabolic Disorders
Details : IGC-1A is a potential new GLP-1 agonist. Currently, it is being evaluated in the discovery stage for the treatment of patients suffering from diabetes.
Brand Name : IGC-1A
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 20, 2024
Details:
TGR-63 is an investigational, amyloid beta protein A4 modulator, being evaluated in early-stage clinical trial studies for the treatment of patients suffering from Alzheimer's disease.
Lead Product(s): TGR-63
Therapeutic Area: Neurology Brand Name: TGR-63
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2024
Lead Product(s) : TGR-63
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Preclinical Analyses Show TGR-63's Blood-Brain Barrier Permeability and Safety
Details : TGR-63 is an investigational, amyloid beta protein A4 modulator, being evaluated in early-stage clinical trial studies for the treatment of patients suffering from Alzheimer's disease.
Brand Name : TGR-63
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Details:
IGC Pharma's investigational product TGR-63 is being evaluated in early-stage clinical trial studies for the treatment of patients suffering from Alzheimer's disease.
Lead Product(s): TGR-63
Therapeutic Area: Neurology Brand Name: TGR-63
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : TGR-63
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IGC Pharma's TGR-63 Preclinical Results Show Reduction in Amyloid Plaque in Alzheimer's
Details : IGC Pharma's investigational product TGR-63 is being evaluated in early-stage clinical trial studies for the treatment of patients suffering from Alzheimer's disease.
Brand Name : TGR-63
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Lead Product(s): IGC-AD1
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
IGC Announces Patient Enrollment at Neurostudies in Ph 2 Trial Investigating IGC-AD1
Details : IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2024
Details:
IGC-AD1 (tetrahydrocannabinol) is a small molecule drug that targets neuroinflammation and CB1 receptor dysfunction. It is being evaluated for the treatment of alzheimer disease.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
Details : IGC-AD1 (tetrahydrocannabinol) is a small molecule drug that targets neuroinflammation and CB1 receptor dysfunction. It is being evaluated for the treatment of alzheimer disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2024
Details:
The net proceeds will be used for advancing company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, for agitation in dementia from Alzheimer’s disease.
Lead Product(s): Tetrahydrocannabinol,Melatonin
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Bradbury Asset Management
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 26, 2024
Lead Product(s) : Tetrahydrocannabinol,Melatonin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bradbury Asset Management
Deal Size : $3.0 million
Deal Type : Private Placement
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
Details : The net proceeds will be used for advancing company's investigational medicines including IGC-AD1, a natural THC-based oral formulation, for agitation in dementia from Alzheimer’s disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 26, 2024
Details:
IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Lead Product(s): IGC-AD1
Therapeutic Area: Neurology Brand Name: IGC-AD1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
IGC Pharma Reports Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Details : IGC-AD1 is the first natural cannabis-based formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Brand Name : IGC-AD1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2024
Details:
TGR-63 disrupts amyloid-β peptide structure, reducing memory loss and learning impairments in Alzheimer’s disease. It is being developed for treating cognitive decline in Alzheimer’s patients.
Lead Product(s): TGR-63
Therapeutic Area: Neurology Brand Name: TGR-63
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Lead Product(s) : TGR-63
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
Details : TGR-63 disrupts amyloid-β peptide structure, reducing memory loss and learning impairments in Alzheimer’s disease. It is being developed for treating cognitive decline in Alzheimer’s patients.
Brand Name : TGR-63
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?